Investigational drug · Phase 2
MK-8690
Also called: PRA052
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colitis Ulcerative, Ulcerative Colitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MK-8690"
First trial start
2026
Mar 24, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-8690", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colitis Ulcerative
- Ulcerative Colitis
Approved drugs for the same conditions: Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-8690" as an intervention, largest first.
- A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07463183 · 100 participants (planned) · Start Mar 24, 2026 · Primary completion Oct 28, 2027
Drug: MK-8690 · For: Colitis Ulcerative; Ulcerative Colitis
Sites: Anaheim, California; Coronado, California; Colorado Springs, Colorado · 43 sites in all
- A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)Not yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07895524 · 60 participants (planned) · Start Nov 23, 2026 · Primary completion Oct 19, 2027
Drug: Methotrexate (MTX) · For: Rheumatoid Arthritis
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Colitis Ulcerative
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.